BiotechTubeBiotechTube
Home/Axsome Therapeutics/Dr. Mark Coleman
DM

Dr. Mark Coleman

Director, Board of Directors

Axsome Therapeutics

Therapeutic Areas

Central Nervous SystemDepressionMigraineSleep DisordersAlzheimer's DiseaseNarcolepsyFibromyalgia

Axsome Therapeutics Pipeline

DrugIndicationPhase
Auvelity (AXS-05)Major Depressive DisorderApproved
Sunosi (Solriamfetol)Excessive Daytime SleepinessApproved
SymbravoMigraineApproved
AXS-05Alzheimer's Disease AgitationPhase 3
AXS-12Narcolepsy with CataplexyPhase 3
AXS-14FibromyalgiaPhase 3
Solriamfetol (CLARITY Trial)Major Depressive Disorder with Excessive Daytime SleepinessPhase 3

Leadership Team at Axsome Therapeutics

DH
Dr. Herriot Tabuteau
Chief Executive Officer and Founder
NP
Nick Pizzie
Chief Financial Officer
MJ
Mark Jacobson
Chief Operating Officer
HM
Hunter Murdock
General Counsel
AM
Ari Maizel
Chief Commercial Officer
DR
Dr. Roger Jeffs
Director, Board of Directors
DS
Dr. Susan Mahony
Director, Board of Directors
View full Axsome Therapeutics profile